Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 6

Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

November 1, 2024

Ajay Chari, MD, Noopur S. Raje, MD, Adriana Rossi, MD, Weill Cornell Medical College, Natalie Callander, MD, Tom Martin, MD

Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

Now Viewing

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP. 7: Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP. 8: CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

EP. 9: Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP. 10: Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

Dr Ajai Chari to Dr Callander: What factors (disease or patient) do you consider when deciding between a triplet vs quadruplet induction regimen for those who are transplant ineligible?
Dr Ajai Chari to Dr Raje: What unmet needs still exist in the treatment paradigm of newly diagnosed multiple myeloma, both transplant eligible and ineligible?